Michigan, US-based biopharmaceutical firm ProNAi Therapeutics landed $60 million in its Series D funding round led by Vivo Capital to advance its cancer treatment drugs to the second phase of clinical trials.
RA Capital Management
Breaking News
- Joe Biden Bashes Donald Trump for Inheriting His Wealth as He Touts His Middle-Class Upbringing in Union Speech
- ASML's Potential Exit from the Netherlands: Dutch Minister Remains Optimistic About Company's Future
- Shipping Industry Calls on UN to Protect Vessels, Seafarers Following Iran's Seizure of MSC Aries Container Ship
Cambridge-based anti-obesity drug developer Zafgen Inc bagged another USD45 million in a Series E funding round today, bringing its total funding to date to USD114 million.
Subscribe to VCpost newsletter
Most Popular
- American Millionaire Charged in Brutal Murders of Canadian Tycoon and His Partner in Dominica Denied Bail
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Tesla Spends $200,000 in Promoting Elon Musk's Social Media Platform X Following Mention of 'Minimal Advertising Efforts'
- Michigan Family Sues Wendy's for $20 Million After 11-Year-Old Girl Suffered Deadly E.Coli Infection
- Brazilian Woman Wheels Her Dead Uncle Into the Bank to Withdraw Loan in His Name
- Australian Farmer Prepares Grave of 3,000 Sheep After Failing to Find Buyer
- Sheetz Convenience Store Accused of Racial Discrimination After Denying Employment of Black, Mixed-Race, and Native American Applicants
